ExodusPoint Capital Management LP Purchases Shares of 139,748 Sage Therapeutics, Inc. (NASDAQ:SAGE)

ExodusPoint Capital Management LP acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,748 shares of the biopharmaceutical company's stock, valued at approximately $759,000. ExodusPoint Capital Management LP owned 0.23% of Sage Therapeutics at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. State Street Corp raised its position in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock worth $21,127,000 after purchasing an additional 451,377 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Sage Therapeutics by 157.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company's stock worth $918,000 after acquiring an additional 103,495 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company's stock valued at $3,265,000 after acquiring an additional 43,617 shares during the period. Thrivent Financial for Lutherans grew its position in Sage Therapeutics by 108.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock valued at $405,000 after acquiring an additional 38,876 shares during the last quarter. Finally, Fox Run Management L.L.C. increased its stake in Sage Therapeutics by 199.0% in the fourth quarter. Fox Run Management L.L.C. now owns 48,950 shares of the biopharmaceutical company's stock worth $266,000 after purchasing an additional 32,579 shares during the period. 99.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on SAGE. Canaccord Genuity Group cut their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Scotiabank lowered their price target on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a report on Wednesday, February 12th. HC Wainwright restated a "neutral" rating and set a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Bank of America assumed coverage on Sage Therapeutics in a report on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 target price for the company. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $8.81.

Sage Therapeutics Trading Up 1.2 %

Shares of SAGE stock traded up $0.09 during trading hours on Thursday, reaching $7.46. 162,637 shares of the company's stock were exchanged, compared to its average volume of 1,242,320. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $14.97. The stock's 50 day moving average is $7.46 and its 200-day moving average is $6.72. The company has a market cap of $458.34 million, a price-to-earnings ratio of -1.13 and a beta of 0.48.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Equities analysts anticipate that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.